Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Clearside Biomedical excels in 2022, eyes trial milestones and partnerships

Clearside Biomedical's strong performance in 2022, supported by key achievements and financial stability, positions the company well for future growth and innovation.
While facing challenges such as trial design adjustments and addressing analyst inquiries, Clearside's strategic partnerships and upcoming trials offer significant opportunities for expansion and market advancement.

Clearside Biomedical reports positive OASIS trial results and financial stability

Clearside Biomedical's Q1 2023 performance reflects advancements in CLS-AX development and financial stability
Challenges include addressing analyst inquiries and potential resistance to extended duration treatments
Opportunities lie in leading treatment innovation and expanding investor engagement through conferences and filings

Clearside Biomedical advances in wet AMD treatment with innovative approach

Clearside Biomedical's Q2 2023 earnings call highlighted strong progress in their lead program, financial stability, and innovative delivery technology, positioning them well in the market.
The company's differentiated mechanistic approach and potential for combination therapies offer competitive advantages and opportunities for market expansion.
While facing challenges in proving efficacy, financial sustainability, and market adoption, Clearside's strategic collaborations and diverse portfolio present avenues for growth and success.

Clearside Biomedical advances trials and partnerships, eyes growth opportunities

Clearside Biomedical's Q3 2023 Earnings Call highlighted progress in trials, partnerships, and cash position. Challenges include trial enrollment and design considerations, while opportunities exist in value creation and milestone achievements by partners.

Clearside Biomedical reports positive 2023 progress and financial stability

Clearside Biomedical made significant progress in 2023, with a focus on advancing key clinical programs and collaborations.
Financially, the company is well-positioned with sufficient resources to support operations until the third quarter of 2025.
Challenges lie in successfully completing ongoing trials and maintaining competitiveness in the evolving landscape of vision treatments.
Opportunities abound in innovative drug delivery approaches, therapeutic advancements, and strategic collaborations for Clearside.

Clearside Biomedical reports stable finances and bullish outlook on CLS-AX

Clearside Biomedical's Q1 2024 earnings call highlighted a stable financial position, key leadership additions, and the promising potential of CLS-AX in treating retinal diseases. Analyst inquiries underscored areas of interest and scrutiny, pointing to the company's need for continued strategic development and adherence to regulatory standards.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside's Suprachoroidal Space (SCS ® ) Delivery Platform - ALPHARETTA, Ga., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the Company's Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical Co., Ltd.

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

ALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m. ET in New York, NY.

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Tony Gibney as Chair of its Board of Directors, effective November 1, 2024. Mr. Gibney, who joined Clearside's Board as an independent director in April 2024, succeeds Clay Thorp, who will continue serving as a member of the Board.

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2024 financial results will be reported on Tuesday, November 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

- CLS-AX Phase 3 Ready Based on Positive Phase 2b Topline Data in Wet AMD - - Differentiated Profile for CLS-AX Targeting Flexible Dosing Similar to a Biologic with the Potential Extended Duration of a Tyrosine Kinase Inhibitor (TKI) - - Versatility of SCS Microinjector ® Featured in Multiple Presentations - ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple presentations were delivered at the 2024 Annual Meeting of the American Academy of Ophthalmology (AAO) and preceding events that highlighted encouraging safety and efficacy data from clinical trials of therapies utilizing Clearside's SCS Microinjector® to deliver drugs into the suprachoroidal space to treat a variety of retinal diseases.

Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

- Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events - - 67% of CLS-AX Participants Did Not Require Any Additional Treatment up to 6 Months - - Reduced Treatment Burden by 84% Over 6 Months - - Webcast and Conference Call Today at 8:00 A.M. ET with Management and  Key Opinion Leader and Board-Certified Retinal Specialist, Roger Goldberg, M.D.

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside's Proprietary SCS Microinjector ® -

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical (CLSD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD)

Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.15 per share a year ago.

Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates

ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that management will present a corporate update at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference which will be available on demand on Thursday, August 15, 2024, at 7:00 a.m. ET. Victor Chong, MD, MBA, Chief Medical Officer, will also participate in a panel discussion on the Evolving Therapeutic Landscape of AMD.

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Clearside Biomedical (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2024 financial results will be reported on Monday, August 12, 2024, after the close of the financial markets.

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Suprachoroidal Space Drug Delivery Call July 24, 2024 8:00 AM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Glenn Yiu - Scientific Advisory Board Victor Chong - Chief Medical Officer David Brown - Director of Research, Retina Consultants Houston Conference Call Participants Annabel Samimy - Stifel Andreas Argyrides - Oppenheimer & Co. Serge Belanger - Needham & Company Yi Chen - H.C. Wainwright Operator Greetings, and welcome to the Clearside Biomedical KOL Webinar.

Clearside Biomedical, Inc. (CLSD) Suprachoroidal Space Drug Delivery (Transcript)

ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), has opened registration for its virtual key opinion leader (KOL) event on Wednesday, July 24, 2024 from 8:00 - 9:15 am ET. To register for the event, click here.

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company's research and development programs.

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ALPHARETTA, Ga., June 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced plans to host a virtual key opinion leader (KOL) event on Wednesday, July 24, 2024 from 8:00 - 9:15 am ET.

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

Oppenheimer initiated coverage on Clearside Biomedical Inc CLSD, a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space.

Why Is Clearside Biomedical Stock Gaining Today?

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector ® - ALPHARETTA, Ga., June 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral presentations were delivered at the Clinical Trials at the Summit (CTS) Meeting on June 8, 2024 in Park City, Utah.

Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery -

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Remy Bernarda - Investor Relations George Lasezkay - Chief Executive Officer Victor Chong - Chief Medical Officer Charlie Deignan - Chief Financial Officer Conference Call Participants Jon Wolleben - JMP Securities Operator Greetings, and welcome to the Clearside Biomedical First Quarter 2024 Financial Results and Corporate Update Conference Call. As a reminder, this conference call is being recorded.

Clearside Biomedical, Inc. (CLSD) Q1 2024 Earnings Call Transcript

Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.15 per share a year ago.

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates

- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga.

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 9:30 a.m. ET in New York, NY.

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S.

News for Clearside Biomedical Stock (CLSD)